Article
Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML.
Carcinogenesis - 12 Aug 2020
O'Brien Gráinne, Cruz-Garcia Lourdes, Zyla Joanna, Brown Natalie, Finnon Rosemary, Polanska Joanna, Badie Christophe
Abstract excerpt
Therapy-related and more specifically radiotherapy-associated acute myeloid leukaemia (AML) is a well-recognized potential complication of cytotoxic therapy for the treatment of a primary cancer. The CBA mouse model is used to study radiation leukaemogenesis mechanisms with Sfpi1/PU.1 deletion and point mutation already identified as driving events during AML development. To identify new pathways, we analysed 123...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
